The estimated Net Worth of Ali Behbahani is at least 275 百万$ dollars as of 17 July 2023. Ali Behbahani owns over 333,333 units of Oyster Point Pharma Inc stock worth over 273,344,019$ and over the last 10 years he sold OYST stock worth over 1,220,183$. In addition, he makes 377,917$ as Chairman of the Board at Oyster Point Pharma Inc.
Ali has made over 20 trades of the Oyster Point Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 333,333 units of OYST stock worth 999,999$ on 17 July 2023.
The largest trade he's ever made was buying 12,000,000 units of Oyster Point Pharma Inc stock on 7 September 2018 worth over 20,040,000$. On average, Ali trades about 789,252 units every 20 days since 2014. As of 17 July 2023 he still owns at least 24,471,264 units of Oyster Point Pharma Inc stock.
You can see the complete history of Ali Behbahani stock trades at the bottom of the page.
Dr. Ali Behbahani M.D. serves as Chairman of the Board of the Company. Dr. Behbahani joined New Enterprise Associates (NEA) in 2007 and is currently a general partner on the healthcare team. Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners from 2000 to 2002 and as a Healthcare Investment Banking Analyst at Lehman Brothers from 1998 to 2000. He has been a member of the board of directors of Genocea Biosciences (Nasdaq:GNCA) since February 2018, CRISPR Therapeutics (Nasdaq:CRSP) since April 2015, and Adaptimmune Therapeutics (Nasdaq:ADAP) since September 2014, Black Diamond Therapeutics, Inc. (Nasdaq:BDTX) since December 2018 and was on the board of Nevro Corp. (NYSE:NVRO) from August 2014 to March 2019. Dr. Behbahani received a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University, an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine. Behbahani is qualified to serve on our Board due to his experience in the biopharmaceutical industry and his experience as a member of the boards of directors of multiple companies in the industry.
As the Chairman of the Board of Oyster Point Pharma Inc, the total compensation of Ali Behbahani at Oyster Point Pharma Inc is 377,917$. There are 7 executives at Oyster Point Pharma Inc getting paid more, with Jeffrey Nau having the highest compensation of 4,037,700$.
Ali Behbahani is 43, he's been the Chairman of the Board of Oyster Point Pharma Inc since 2020. There are 5 older and 1 younger executives at Oyster Point Pharma Inc. The oldest executive at Oyster Point Pharma Inc is William Link, 74, who is the Independent Director.
Ali's mailing address filed with the SEC is 2855 SAND HILL ROAD, , MENLO PARK, CA, 94025.
Over the last 5 years, insiders at Oyster Point Pharma Inc have traded over 24,486,000$ worth of Oyster Point Pharma Inc stock and bought 3,552,871 units worth 59,028,668$ . The most active insiders traders include Ali Behbahani、Venture Capital Vi, L.P.Ver...、Clare Ozawa. On average, Oyster Point Pharma Inc executives and independent directors trade stock every 27 days with the average trade being worth of 2,204,444$. The most recent stock trade was executed by Daniel Lochner on 1 November 2021, trading 8,590 units of OYST stock currently worth 98,871$.
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.
Oyster Point Pharma Inc executives and other stock owners filed with the SEC include: